Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Oriola, Webcast, Q3'25

By Inderes10/30/2025, 8:00 AM
Oriola

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Dennis O'Neil
00:01 - 00:55

Good morning everyone, and a warm welcome to Oriola's Q3 results webcast. I am Dennis O'Neil from Oriola's Investor Relations. With me today, I have our CEO, Katarina Gabrielsson, and CFO, Matz Danielsson. After the presentations, we will open up for your questions. And as a reminder, we will first focus on the questions relating to Oriola's business and financial performance. As usual, you can start posting your questions through the chat already during the presentations. As a reminder, we are also recording the webcast, and the recording will be available on our website later today. And next, we can have a look at the customary disclaimer. And now, without further ado, Katarina, please go ahead.

Katarina Gabrielsson
00:55 - 08:11

Thank you, and welcome also on my behalf. This is the agenda for today. It's quite a traditional agenda. Agenda from our side. So we'll start with the quarter three highlights. Then moving on to the operating environment, we'll go through the segments. Then Matz will take us through the Financial Review before we go to the Q&A. So let's now start with the quarter three highlights. And I'm really, really happy today to stand here and say that the sales margin and the improved adjusted EBITDA have been favorable for us this quarter. The net sales and the sales margin have grown, supported by both of our segments. The high volumes have partly contributed to this, and there were also earlier vaccine deliveries at the end of the third quarter. This has resulted in a higher increased sales margin. Additionally, we experienced an increase in operating expenses towards the end of the quarter. The net sales landed at 9% above the previous year at €463 million. The supply chain operations have been stable during this quarter. And that's a result of the implemented strategic initiatives that we have been doing not only during this quarter but also throughout the year overall, where we, for example, can see increased warehouse capacity as one result of this. And all of this has meant that adjusted EBITDA has improved from the previous year, and we landed on €9.6 million. So, that's that. I would also like to take this opportunity to thank everyone at Oriola. I normally do that at the end, but I would like to do that at the beginning because this is something we can't do without our people and our personnel, and also, of course, our customers and owners who believe in us. The ERP project is entering the first phase of deployment in Sweden, and it's crucial for us as we continue with the strategic initiatives we have. So I'm looking forward to seeing that entering Sweden now through the joint venture company Kronans Apotek, we can see that the market share remains stable. Sales grew by 3%, driven by both physical pharmacies and the e-commerce segment in this area. If we then look at our operating environment, we don't have any major changes in the operating environment. Since we were having this presentation last time during the quarter, Secondly, what we can see is that the value of the pharmaceutical distribution market is growing in both countries, especially in Sweden. It's a little bit flatter in Finland. Especially in Sweden, it's growing. The consumer confidence is weak in both Finland and Sweden. We can see some signs in Sweden now that it will hopefully start to change a little bit. That will then be favorable for us in the future. However, consumer confidence has remained weak during the quarter. Then going to our distribution segments, in the distribution segments where we have pharmacy pharmaceuticals that we distribute from the pharmaceutical wholesaler to pharmacies and hospitals, for example, we can see that the net sales grew by 6% and landed on €373 million. The volume is growing, expanding the total portfolio and also attracting new customers. So we can see that we haven't lost any customers during this quarter. So we have retained all existing customer contracts. We have had earlier vaccine deliveries that I mentioned before in Sweden, and we can also see that the overall market growth has positively affected the sales margin. We have a slight increase in the OpEx due to high volumes, and we can see that additional warehouse capacity and personnel are also contributing to the increase in OpEx. One part of this, especially towards the end of the quarter when we have the vaccines, is giving us higher costs. Since it's earlier this year compared to last year, this impacts the segment. The adjusted EBITDA increased to €8.4 million. And I'm really, really happy to see that this segment is continuing to deliver, as it is also the biggest segment we have in the distribution segment. We are really focusing on customer centricity and strong partnerships, and we can really see that customer satisfaction is continuing to improve. And this has continued to improve now for quite many quarters, and that will give us the possibility to retain both the existing customer accounts for the future. But we also have many expected new contracts to come, and that will affect us, mainly in the second part of 2026, since we know that once we have signed a contract, it will take some time before it goes into the real production parts. If we then look at the wholesale segment, I'm really pleased to see that the net sales grew by 23% to €91 million. In Sweden, we have growth supported by good development in the parallel import of weight loss medicines, and in Finland, we see solid performance in sales, especially to veterinarians in the specialist medicines area. We can't see in this segment that the growth is impacting the EBITDA positively at this point. The positive sign here is that if we look at the first half of this year, we weren't on the year-to-year comparison level. But in this quarter, we are now at the same level as we were last year. And that is a positive sign where we can see that both the growth and our cost consciousness are really having an effect. And why is EBITDA not at a high level when we have this net sales growth? The main reason is that we have an unfavorable product mix, since we have a slightly lower margin in parallel imports than in the other segments, and also higher operating expenses than expected based on the volumes we have. The other part of the wholesale segment is the advisory products. Here we can see the positive development in digital and data services, which has continued to grow with double-digit growth. There is also a segment in the advisory that we will really focus on in the future. Overall, we are now looking at new customer acquisitions, and we can see that they are coming. And we have also built a partner network for EU-wide assignments. That means that we can take on some different assignments that were previously not possible for us to undertake. We have also made some investments in the wholesale segments, particularly in the brands that we have in Finland. And what you see on this slide is also our Apteekkarin brand, where we have done a rebranding to better align with customer expectations and today's consumer to make it a little bit more modern. With that, I'm done with the business review, and we will then go on with the financial review. Please proceed.

Matz Danielsson
08:16 - 16:18

Thank you, Katerina, and welcome also from my side to this session. We will start from the top line and look at invoicing and net sales. We had good growth this quarter. It has continued during the year. In the distribution segment, our existing customers are growing. We have also seen that the new customers we have onboarded have been growing very well. We have in the distribution segment also started with vaccine deliveries slightly earlier than last year. So in September, we have been handling those, which has also generated more invoicing. We are also involved in the wholesale business. We have, as Katharina mentioned, the parallel import, which has generated net sales in that part. Overall, if you look at the year-to-date numbers. So we are experiencing good growth, mainly driven by the larger distribution business. Sales margin, of course. As I said before, it is crucial for a key performance indicator that we follow closely in the company. We have been growing each quarter, and it's mainly been driven by the distribution business. Now, we also had a good quarter in the wholesale business, generating sales margin. We have, year to date, increased the sales margin by 6.3 million. This is mainly driven by the growth in the business. Driving for more volumes and a higher sales margin. Looking at the EBITDA, we have had a good quarter. As said, wholesale was flat compared to last year. We have had a decline in the EBITDA in wholesale the first two quarters, but now it was flat. And we also have a tight cost control in place. So we try to increase profitability by monitoring the costs very closely. Also, if we look at the adjusting items now, we have much more than last year. It's the ERP project mainly driving those. We also had the DOE Sweden impacting the adjusting items. And then we have some smaller topics there. We have a feasibility study on the manga distribution center also included in there. But that brings the reported EBITDA down to a lower level of 14.5 million. If we look at the distribution segment, the good growth is continuing. It's with the new and current customers that we have, and as said, also in the quarter there were some more vaccine deliveries, positively affecting the quarter with a 10% growth year on year. In the first quarters, the EBITDA is growing. It's related to the volume growth and follows the same pace as the beginning of the year. The wholesale segment had good growth, partly dependent on the parallel import related to weight loss medicines in Sweden. A 16% increase year-to-date in adjusted EBITDA. As stated in the quarter, it was flat. If we look at the year to date, we are still lower than last year. However, it was a good development during this quarter. If we look at the net profit, we have had, as said, more adjusting items affecting the reported EBITDA. And then we have some other small improvements, but we are landing on a -9.3 million negative net profit, which is lower than last year. Free cash flow, even though we have a lower EBITDA, we have better cash flow mainly related to the working capital items where we have volatility in the working capital. So it might go a bit up and down depending on the reporting day. But in general, the trend is, of course, towards negative working capital. So the more we invoice and sell, the better the cash flow will be. If we look at the net debt, we see a slight change from the last quarter. But compared to a year ago, we are on a lower level than that. So the net interest-bearing debt has been improving. If we look at the equity ratio, it has now been at a 13% level. We know that this is, of course, as earlier said, affected by the ERP project and impairments that we have had during this year and also last year. We know that the ERP project is burdening the equity ratio, but we know that there will be an end to that also. While we are taking all the costs now in the profit and loss, we know that we will have almost no depreciations from this implementation. After that, the gearing, of course, is on a good level. Due to good cash flow in general. Kronans is doing a bit better this quarter, having a small positive impact on our numbers. Also, uh, good. With Krona, their market share remained stable this quarter. Not gaining, not losing any market share. They are now finalizing and completing the ERP project and integration project during the last quarter. So, then that will be ready and rolled out. We are keeping the outlook unchanged. We are expecting the EBITDA to increase from the previous year. And there is no change on that. Then if we look at the equity ratio and gearing, the equity ratio has now been at a 13% level. That was my part.

Katarina Gabrielsson
16:18 - 17:09

And I think you can stay here for the questions. Then if we look at the equity ratio and gearing, the equity ratio has been now at a 13% level. Like I said when I started this one, I'm really happy about the result we have. I really see that we have solid third-quarter results, and that the sales and sales margin are growing in a positive way as they did at the beginning of the year. I'm also really pleased to see now, because last time we said that we didn't get the pass-through margin. It's not where we want it to be, but we can see that we're also improving now in adjusted EBITDA, on another level than we did at the beginning of the year. But with that said, of course, the focus for the rest of the year is really to continue to grow the sales and sales margins, while also remaining cost-conscious because we really want to grow the EBITDA even more. So with that, let's go to the questions.

Dennis O'Neil
17:09 - 18:03

Then, if we look at the equity ratio and gearing, the equity ratio has been at a 13% level. So thank you, Caterina, for your presentations. And we already have some questions in the chat. As a reminder to everyone, Keep on sending them to us and we will. I will try to group the questions so that we first start with the questions relating to Oriola Corporation. And if there are any questions relating to Kronans Apotek, we will take them last. Okay. So let's start here then. This one goes to Mats. It's about the equity ratio. So the equity ratio is 12.9% in Q3. What level of equity ratio would be too low, resulting in financial or business problems for Oriola, or meaning fewer dividends than Oriola has paid in the past two years?

Matz Danielsson
18:04 - 18:41

Yeah, I would say that we are, we are. We are a growing company with a good cash flow. So, the equity ratio is something we follow very closely. Also, we know that we have a lot of adjusting items, and we have had impairments that have affected the equity ratio. We do not see that we currently have any problems with the equity ratio. I think that it's partly understood that we have a heavy burden from the ERP project currently, so that has an effect on it. But we know that after the project, it will be a totally different game at that time.

Dennis O'Neil
18:42 - 18:53

I will try to group the questions so that we first start with the questions relating to Oriola. So you ended with the ERP. So let's continue with that. So we have a question about when the ongoing ERP project will have a positive impact on EBITDA.

Matz Danielsson
18:54 - 19:15

It will have a positive impact, I mean the main part of the project is planned for 2025, 2026, and 2027. And we will see gains directly after that and during all the phases starting to emerge. We'll also see improvements starting in 2027 and 2028 from the projects. In 2027 and 2028, we will start to see gains from the projects.

Dennis O'Neil
19:16 - 19:36

Good. I will try to group the questions so that we first start with the questions relating to Oriola. So then there's a question relating to the distribution segment. So this goes to Katarina. Will the new customer agreements in the distribution segment affect profitability before the expected pickup in invoicing during H2 26?

Katarina Gabrielsson
19:37 - 19:54

What we have is that we have implemented customers during this year. And of course, that will affect the first part of the next year. Since we don't have the year-to-year comparison on these ones yet. So with that said, yes, it will be positive.

Dennis O'Neil
19:56 - 20:04

Good. And then the question on the wholesale segment. So how do you see the profitability of the wholesale segment developing in the near term?

Katarina Gabrielsson
20:05 - 20:30

Of course, we're not providing guidance for the quarterly part here. But like I said before, we need to see that the wholesale segment is continuing to grow. But we also then need to get more profit in that segment. It's good. Now, we see that it's starting to be on the same level as last year. But of course, it should also continue to grow to meet the expectations we have set in our strategy.

Dennis O'Neil
20:31 - 20:43

Since we don't have the year-to-year comparison on these ones yet. Since we don't have the year-to-year comparison on these ones yet, it will be positive. So then, another question. So could you provide some insight on the adjusted costs related to the feasibility study of logistics operations?

Matz Danielsson
20:45 - 20:58

Well, as we have said before, we are looking at this topic. And of course, there's usually a cost associated with the tasks you undertake, and that work is ongoing.

Katarina Gabrielsson
20:59 - 21:02

And we will communicate more when we are ready to communicate.

Dennis O'Neil
21:03 - 21:17

Good. Since we don't have the year-to-year comparison on these ones yet, it will be positive. And then there's a question relating to the vaccines. So how meaningful was the impact of the timing of vaccines on Q3 earnings? Maybe top-line and bottom-line comments.

Katarina Gabrielsson
21:18 - 21:42

I don't have the total number for that right now. I apologize. I apologize for that. But what we can see is that we have delivered more during quarter three, but we still have a substantial part in the fourth quarter. But normally, most of the vaccines are delivered in quarter four. And also then the costs. So that's what we mean when we say it's coming a little bit earlier. The substantial part is still in quarter four.

Dennis O'Neil
21:43 - 22:22

Good. Thank you. So these were all the questions we have at the moment in chat related to Oriola Corporation. So if we wait another few minutes for more questions, let's address a question relating to Kronans Apotek. The valuation of the JV in the balance sheet is €360.306 million in Q3. The valuation is based on technical IFRS equity calculation. Does Oriola see any risks downward in the valuation, or does Oriola see more possibilities upward in this valuation?

Matz Danielsson
22:23 - 22:42

We don't really guide on that, but we do impairments every year and whenever there is a significant change in something, so we keep a close eye on that.

Dennis O'Neil
22:43 - 23:08

Good. So that's what we mean by it's coming a little bit earlier. So I think this was all from the chat. So, I would like to thank everyone who has joined us today. And our next webcast will take place on the 25th of February when we publish the full year results for 2025. And until then, if you have any questions, please don't hesitate to contact us. We wish you all a good rest of the week.

Katarina Gabrielsson
23:08 - 23:09

Thank you.

Matz Danielsson
23:09 - 23:09

Thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…